Compare · NYMX vs ORKA
NYMX vs ORKA
Side-by-side comparison of Nymox Pharmaceutical Corporation (NYMX) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NYMX and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $6.74B, about 56.4x NYMX ($119.6M).
- ORKA has hit the wire 11 times in the past 4 weeks while NYMX has been quiet.
- ORKA has more recent analyst coverage (11 ratings vs 0 for NYMX).
- Company
- Nymox Pharmaceutical Corporation
- Oruka Therapeutics Inc.
- Price
- -
- -
- Market cap
- $119.6M
- $6.74B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 0
- 11
- Recent ratings
- 0
- 11
Nymox Pharmaceutical Corporation
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, The Bahamas.
Latest NYMX
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
Latest ORKA
- Chief Commercial Officer Edwards Larry Todd was granted 100,000 shares (SEC Form 4)
- SEC Form 3 filed by new insider Edwards Larry Todd
- Oruka Therapeutics Inc. filed SEC Form 8-K: Leadership Update
- Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
- SEC Form S-3 filed by Oruka Therapeutics Inc.
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $782,882 worth of shares (7,000 units at $111.84) as part of a pre-agreed trading plan (SEC Form 4)
- General Counsel Quinlan Paul T exercised 52,000 shares at a strike of $11.60 and sold $5,641,409 worth of shares (52,000 units at $108.49) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun exercised 10,000 shares at a strike of $15.69 and sold $1,066,572 worth of shares (10,000 units at $106.66) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by Oruka Therapeutics Inc.
- Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update